EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, announced th...
Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. have officially announced a definitive agreement for Genmab's acquisition of ProfoundBio in an all-cash dea...
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company specializing in allosteric modulation-based drug development,...
AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a trailblazing clinical-stage biopharmaceutical company speciali...
The deal, valued at up to $1.05 billion, comprises an $800 million upfront payment and an additional $250 million contingent upon r...
– Proceeds will be used to complete clinical demonstration trials of the lead candidate drug RNDP-001 for the treatment of Parkinson's di...
Curve Therapeutics, a pioneering biotechnology firm, announced a significant £40.5 million Series A funding round, led by Pfizer Ventures and joined ...
Aizon, the AI SaaS provider transforming pharmaceutical manufacturing, announced today the closing of a $20 million...
In a move that adds an intriguing layer to the IPO dynamics, Alto has granted underwriters a 30-day option to scoop up an additional 1,206,000 shares of co...
Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin of 29.8% Continued growth inves...
Pfizer does not endorse TRC Capital Investment’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in respons...
QIAGEN announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase tha...
Inaugural strategy is one of the largest ever first-time private life sciences growth funds Fundraise closed above its original target, reflecting stron...
"Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this sp...
© 2025 Biopharma Boardroom. All Rights Reserved.
